Piramal Finance reported a standalone net profit of Rs 529.21 crore for the September 2026 quarter, nearly doubling from Rs 277.67 crore year-on-year. The company successfully raised Rs 2,099.99 crore via a QIP to fuel its lending business and finalized a preferential warrant issue to promoters. Shareholders should watch for progress on the ongoing amalgamation of its subsidiary entities and the future conversion of these warrants.
Piramal Finance Reports Strong Q2 Growth and Capital Infusion
Standalone net profit for the September 2026 quarter rose to Rs 529.21 crore, up from Rs 277.67 crore in the same period last year. Total income for the quarter climbed to Rs 3,683.06 crore compared to Rs 2,869.85 crore a year ago.
Reader Takeaway: Strong profit growth and successful capital raising provide liquidity, though NCLT amalgamation timelines remain a watch point.
What just happened
Piramal Finance has released its financial results for the quarter and half-year ended September 30, 2026. Simultaneously, the company confirmed the successful completion of a Qualified Institutions Placement (QIP), raising Rs 2,099.99 crore through the issuance of over 9.9 million shares. Additionally, the company has allotted warrants to its promoter entity, Nithyam Realty Private Limited, at Rs 2,110 per warrant, strengthening the capital base.
Why this matters
The jump in profitability highlights sustained momentum in the company's lending operations. The capital raised through the QIP is earmarked primarily for lending activities, signaling management's intent to capture further market share. The promoter-led warrant issuance further cements confidence in the company’s long-term growth trajectory.
Corporate Developments
The company is currently steering a Scheme of Amalgamation involving key subsidiaries including Piramal Corporate Tower Private Limited, Piramal Agastya Offices Private Limited, and DHFL Investments Limited. This process is currently awaiting final sanction from the National Company Law Tribunal (NCLT).
Risks to watch
Regulatory approval is the primary hurdle for the pending amalgamation. Any delays in the NCLT process could impact organizational restructuring timelines. Investors should also track the exercise of the 82,94,000 warrants, which could lead to equity dilution over the next 18 months as they are converted in tranches.
What to track next
Watch for updates on the NCLT hearings regarding the amalgamation and management commentary on loan book quality and NIMs in the upcoming earnings call.